Showing results (1-10 of 61) with videos related to
Sort By:
Pageof 7
The Journal of Antimicrobial Chemotherapy|June 14, 2005
Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected personsJ Gerardo García-LermaPharmaceutics|June 27, 2025
Expanding the Toolbox of Biomedical HIV Prevention Options Through Innovative DesignJ Gerardo García-LermaCurrent Opinion in HIV and AIDS|September 12, 2012
Animal models of antiretroviral prophylaxis for HIV preventionJ Gerardo García-Lerma, Walid HeneineThe Lancet. Infectious Diseases|December 31, 2002
Mutation rate and the efficacy of antimicrobial drug treatmentPhilip J Gerrish, J Gerardo García-LermaCurrent Opinion in HIV and AIDS|June 28, 2022
The predictive value of macaque models of preexposure prophylaxis for HIV preventionJ Gerardo García-Lerma, Janet M McNicholl, Walid HeneineCurrent Opinion in HIV and AIDS|December 4, 2015
Nondaily preexposure prophylaxis for HIV preventionPeter L Anderson, J Gerardo García-Lerma, Walid HeneineJournal of Virology|December 29, 2006
The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactionsMian-er Cong, Walid Heneine, J Gerardo García-LermaProceedings of the National Academy of Sciences of the United States of America|July 10, 2010
HIV, transmitted drug resistance, and the paradox of preexposure prophylaxisVirginie Supervie, J Gerardo García-Lerma, Walid Heneine, et al.Trends in Pharmacological Sciences|December 8, 2009
Oral pre-exposure prophylaxis for HIV preventionJ Gerardo García-Lerma, Lynn Paxton, Peter H Kilmarx, et al.Journal of Virology|June 29, 2004
Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudineJ Gerardo García-Lerma, Hamish MacInnes, Diane Bennett, et al.Pageof 7